Product Description
Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cefilavancin)
Mechanisms of Action: Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Theravance Biopharma
Company Location: GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Company CEO: Rick E Winningham
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Staphylococcal Infections|Skin Diseases, Infectious|Cellulitis|Staphylococcal Skin Infections|Communicable Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT00442832 | P2 |
Completed |
Cellulitis|Communicable Diseases|Staphylococcal Infections|Skin Diseases, Infectious|Staphylococcal Skin Infections |
2007-05-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/30/2021 |
PubMed |
Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates. |
|
12/04/2020 |
PubMed |
Secretory galectin-3 induced by glucocorticoid stress triggers stemness exhaustion of hepatic progenitor cells. |